Table 1:

Number of participants who acquired single-lineage infections sensitive to VRC01, defined as IC₈₀ ≤ 3 μg/ml.

	HVTN 703/HPTN 081 (Africa Trial)				HVTN 704/HPTN 085 (Americas Trial)
	VRC01 10 mg/kg	VRC01 30 mg/kg	Placebo	Total	VRC01 10 mg/kg	VRC01 30 mg/kg	Placebo	Total
No. HIV-1 diagnosis*	34	24	29	87	37	34	41	112
No. single lineage infections (Env)**	22	11	17	50	19	26	29	74
No. single VRC01 sensitive lineage	9	4	10	23	6	7	11	24
No. individuals with variant VRC01 sites	6	3	2	11	1	3	3	7
No. env sequences at time point 1 median (range)	33 (3–100)	193 (71–245)	123 (23–369)	71 (3–369)	155 (16–324)	104 (3–379)	181 (27–333)	138 (3–379)
No. env sequences at time point 2 median (range)	61 (5–184)	81 (63–216)	80 (4–208)	74 (4–216)	165 (30–192)	112 (28–357)	115 (42–467)	116 (28–467)

^*All participants who acquired HIV-1 were included except for 25 participants with sequence data from only a single time point.

^**Six participants were excluded because their first sequencing time point was ≥45 days from the estimated date of acquisition (range 45–73 days).³¹ Of the 47 single-lineage infections with sensitive viruses, 39 occurred by the week 80 visit (23 from HVTN 703; 24 from HVTN 704) and 8 occurred after the week 80 visit (2 from HVTN 703; 6 from HVTN 704).